| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 03/30/2001 | WO2003044525A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021773A2 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021761A2 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021620A2 Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines |
| 03/29/2001 | WO2001021619A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 03/29/2001 | WO2001021614A1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| 03/29/2001 | WO2001021583A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 03/29/2001 | WO2001021582A1 Biphenyl derivatives used as nhe-3 inhibitors |
| 03/29/2001 | WO2001021259A2 Use and compositions for treating platelet-related disorders using anagrelide |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021177A1 Chemokine/cytokine expression inhibitors |
| 03/29/2001 | WO2001021163A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/29/2001 | WO2001021159A2 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 03/29/2001 | WO2000059875A3 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19945302A1 Biphenylderivate als NHE-3-Inhibitoren Biphenyl as NHE-3 inhibitors |
| 03/29/2001 | DE19944767A1 N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel N-substituted 4-Aminopteridine, processes for their preparation and their use as medicaments |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2387529A1 Biphenyl derivatives as nhe-3 inhibitors |
| 03/29/2001 | CA2387520A1 Amine derivatives |
| 03/29/2001 | CA2385813A1 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2382547A1 Methods and compositions for treating platelet-related disosders |
| 03/28/2001 | EP1086232A1 A vaccine-induced hepatitis b viral strain and uses thereof |
| 03/28/2001 | EP1086225A2 Human tumour-derived polypeptide hormone phosphatonin |
| 03/28/2001 | EP1086131A1 Cyclic somatostatin analogs |
| 03/28/2001 | EP1086113A2 Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use |
| 03/28/2001 | EP1086106A1 Furopyridine derivatives and their therapeutical use |
| 03/28/2001 | EP1086101A1 Beta-carboline compounds |
| 03/28/2001 | EP1086098A1 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| 03/28/2001 | EP1086096A1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| 03/28/2001 | EP1086092A1 BENZO(b)THIEPINE-1,1-DIOXIDE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE |
| 03/28/2001 | EP1086086A1 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 03/28/2001 | EP1086085A1 INHIBITORS OF p38 |
| 03/28/2001 | EP1086066A1 Muscarinic receptor antagonists |
| 03/28/2001 | EP1085905A1 Immunotherapeutic composition and method for the treatment of prostate cancer |
| 03/28/2001 | EP1085894A1 Beta 3-adrenergic receptor agonists |
| 03/28/2001 | EP1085889A2 Novel therapeutic agents that modulate endothelin receptors |
| 03/28/2001 | EP1085887A2 Novel angiotensin receptor modulators and their uses |
| 03/28/2001 | EP1085870A2 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 03/28/2001 | EP1085868A1 H1-histamine receptor antagonists |
| 03/28/2001 | EP1085847A2 Novel therapeutic agents that modulate estrogen receptors |
| 03/28/2001 | EP0775132B1 (azetidin-1-ylalkyl)lactams as tachykinin antagonists |
| 03/28/2001 | CN1289326A N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia |
| 03/28/2001 | CN1289249A Derivatives of 1,3,4-oxadiazolone |
| 03/28/2001 | CN1288743A Prostatitis curing granule |
| 03/28/2001 | CN1288742A Antibacterial and detoxicating medicine powder feilinsan |
| 03/28/2001 | CN1063640C Use of phoenix-tail fern in medicine for treating nephrosis |
| 03/27/2001 | US6207852 Smooth muscle spasmolytic agents, compositions and methods of use thereof |
| 03/27/2001 | US6207811 Nephrin gene and protein |
| 03/27/2001 | US6207805 Hybridoma which secretes monoclonal antibodies; diagnosis; anticarcinogenic agents with reduced side effects; imaging |
| 03/27/2001 | US6207803 Amino acid sequence of polypeptide; anticarcinogenic agents; antitumor agents; treatment of automimmune disorders, blood disorders; alzheimer's/parkinson's disease, septic shock, osteoporosis, polycystic kidney disease; viricides; diagnosis |
| 03/27/2001 | US6207706 Use of COMT inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions |
| 03/27/2001 | US6207693 Benzamide derivatives having a vasopressin antagonistic activity |
| 03/27/2001 | US6207374 Tuberous sclerosis 2 gene and uses thereof |
| 03/27/2001 | US6207180 Intravesical drug delivery |
| 03/27/2001 | CA2201098C Orphan receptor |
| 03/27/2001 | CA2065860C Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix |
| 03/22/2001 | WO2001019983A1 Human g-protein coupled receptor |
| 03/22/2001 | WO2001019977A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 03/22/2001 | WO2001019960A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 03/22/2001 | WO2001019860A2 Proteins associated with cell differentiation |
| 03/22/2001 | WO2001019829A2 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | WO2001019826A2 Triazolopyrimidine derivatives |
| 03/22/2001 | WO2001019825A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | WO2001019819A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | WO2001019816A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 03/22/2001 | WO2001019814A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | WO2001019807A1 2-imino-1,3-thiazine derivatives |
| 03/22/2001 | WO2001019422A1 Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation |
| 03/22/2001 | WO2001019407A2 Taxane prodrugs |
| 03/22/2001 | WO2001019396A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 03/22/2001 | WO2001019387A1 Use of mullerian inhibiting substance for treating excess androgen states |
| 03/22/2001 | WO2001019369A1 Use of thienopyrimidines |
| 03/22/2001 | WO2001019339A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | WO2001019161A2 ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR-β EXPRESSION |
| 03/22/2001 | WO2001005435A3 Antisense therapy for hormone-regulated tumors |
| 03/22/2001 | WO2001000188A3 Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and their use for preventing and/or treating anaemia |
| 03/22/2001 | WO2000078341A8 A method for the prophylaxis and/or treatment of medical disorders |
| 03/22/2001 | WO2000069421A3 Transdermal therapeutic system (tts) containing tolterodine |
| 03/22/2001 | WO2000055155A3 Heterocyclic compounds as adenosine deaminase inhibitors |
| 03/22/2001 | WO2000040612A9 Insulin-like growth factor (igf) i mutant variants |
| 03/22/2001 | WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors |
| 03/22/2001 | DE19944604A1 Aminderivate Amine derivatives |
| 03/22/2001 | DE10036855A1 Neue kristalline Form von 6-Hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophenhydrochlorid New crystalline form of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride |
| 03/22/2001 | CA2393896A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | CA2387123A1 Use of thienopyrimidines |
| 03/22/2001 | CA2385747A1 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | CA2385065A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | CA2384991A1 Use of mullerian inhibiting substance for treating excess androgen states |